Published in Pharmacogenet Genomics on August 01, 2011
Single nucleotide polymorphisms in microRNA binding sites: implications in colorectal cancer. ScientificWorldJournal (2014) 0.85
Single nucleotide polymorphisms in microRNA binding sites of oncogenes: implications in cancer and pharmacogenomics. OMICS (2013) 0.84
Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples. Int J Cancer Res Mol Mech (2015) 0.77
In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants. Pharm Res (2017) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol (2007) 3.79
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis (2006) 2.72
Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem (1992) 2.42
Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest (1998) 1.65
The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem (2000) 1.54
A structural analysis of asymmetry required for catalytic activity of an ABC-ATPase domain dimer. EMBO J (2006) 1.48
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther (2006) 1.45
The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch (2006) 1.40
Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. J Biol Chem (2000) 1.36
Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology (1996) 1.36
Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation (2006) 1.33
Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology (2006) 1.29
MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics (2007) 1.23
Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics (2008) 1.18
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther (2007) 1.16
Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol (2007) 1.16
The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res (2004) 1.14
Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica (2001) 1.14
Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos (2005) 1.14
MRP2 and 3 in health and disease. Cancer Lett (2006) 1.13
Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res (2004) 1.11
Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J Biol Chem (2001) 1.11
Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev (2002) 1.10
Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol (2010) 1.07
Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev (2008) 1.07
Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem (2003) 1.07
Hepatic secretion of conjugated drugs and endogenous substances. Semin Liver Dis (2000) 1.01
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol (2009) 1.01
A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics (2010) 1.01
Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J Biol Chem (2001) 0.99
Identification of an amino acid residue in multidrug resistance protein 1 critical for conferring resistance to anthracyclines. J Biol Chem (2001) 0.99
A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics (2005) 0.99
Nonequivalent nucleotide trapping in the two nucleotide binding folds of the human multidrug resistance protein MRP1. J Biol Chem (2000) 0.99
Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab Dispos (2008) 0.96
Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther (2008) 0.95
Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release (2002) 0.95
Structural requirements for the apical sorting of human multidrug resistance protein 2 (ABCC2). Eur J Biochem (2002) 0.94
Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomed Pharmacother (2005) 0.92
The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J Mol Med (Berl) (1997) 0.91
Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem (2003) 0.91
Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). Mol Pharmacol (2004) 0.90
Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology (2002) 0.90
Identification of regions required for apical membrane localization of human multidrug resistance protein 2. Mol Pharmacol (2008) 0.90
Charged amino acids in the sixth transmembrane helix of multidrug resistance protein 1 (MRP1/ABCC1) are critical determinants of transport activity. J Biol Chem (2002) 0.88
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics (2006) 0.88
Human multidrug resistance protein 2 transports the therapeutic bile salt tauroursodeoxycholate. J Pharmacol Exp Ther (2006) 0.88
Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol Pharmacol (2001) 0.87
Single amino acid substitution of rat MRP2 results in acquired transport activity for taurocholate. Am J Physiol Gastrointest Liver Physiol (2001) 0.87
Determination of free and amidated bile acids by high-performance liquid chromatography with evaporative light-scattering mass detection. J Lipid Res (1992) 0.86
Requirement of a leucine residue for (apical) membrane expression of type IIb NaPi cotransporters. Proc Natl Acad Sci U S A (2000) 0.85
Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology (1999) 0.85
Estradiol 3-glucuronide is transported by the multidrug resistance-associated protein 2 but does not activate the allosteric site bound by estradiol 17-glucuronide. Drug Metab Dispos (2004) 0.83
Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2. Mol Pharmacol (2001) 0.82
MDR1, MRP1 and MRP2 genotypes and in vitro chemosensitivity in Japanese patients with colorectal adenocarcinomas. Kobe J Med Sci (2004) 0.82
Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos (2008) 0.81
Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. Clin Neuropathol (2004) 0.79
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (2004) 4.64
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis (2005) 3.47
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther (2004) 2.81
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology (2006) 2.43
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis (2005) 2.43
Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation (2007) 2.38
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol (2008) 2.11
Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics (2003) 2.03
CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev (2002) 1.86
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med (2003) 1.81
Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther (2005) 1.81
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther (2002) 1.79
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood (2011) 1.77
Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv (2007) 1.74
Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem (2005) 1.56
Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol (2007) 1.56
Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther (2003) 1.53
Shift from biliary to urinary elimination of acetaminophen-glucuronide in acetaminophen-pretreated rats. J Pharmacol Exp Ther (2005) 1.52
Inability to upregulate cytochrome P450 4A and 2C causes salt sensitivity in young Sprague-Dawley rats. Am J Hypertens (2006) 1.48
Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics (2004) 1.47
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis (2006) 1.44
Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem (2003) 1.44
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics (2007) 1.39
Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. Can J Cardiol (2013) 1.39
Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther (2006) 1.37
Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther (2003) 1.31
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics (2011) 1.24
Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther (2007) 1.22
Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis (2006) 1.22
Pharmacogenomics of the OATP and OAT families. Pharmacogenomics (2004) 1.21
Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist (2005) 1.21
Nuclear receptors and drug disposition gene regulation. J Pharm Sci (2005) 1.21
Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res (2008) 1.20
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis (2006) 1.18
Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res (2008) 1.17
Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther (2003) 1.16
MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res (2002) 1.16
Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol (2010) 1.15
P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res (2004) 1.15
Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D-glucuronide-induced cholestasis. Hepatology (2002) 1.14
Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther (2005) 1.13
CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat (2013) 1.13
Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol (2004) 1.12
Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther (2002) 1.10
Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res (2005) 1.10
Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther (2003) 1.10
Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther (2005) 1.09
Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. J Neurochem (2007) 1.08
The Rho1 GTPase acts together with a vacuolar glutathione S-conjugate transporter to protect yeast cells from oxidative stress. Genetics (2011) 1.08
Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev (2008) 1.07
Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther (2006) 1.07
Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos (2005) 1.05
Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res (2009) 1.04
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol (2002) 1.04
Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol (2003) 1.04
Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res (2008) 1.04
p53 Regulates oxidative stress-mediated retrograde signaling: a novel mechanism for chemotherapy-induced cardiac injury. PLoS One (2011) 1.03
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics (2008) 1.03
Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists. ACS Chem Neurosci (2011) 1.03
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics (2006) 1.03
Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol (2010) 1.02
Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol (2002) 1.02
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos (2007) 1.02
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr (2003) 1.01
"Clicked" bivalent ligands containing curcumin and cholesterol as multifunctional abeta oligomerization inhibitors: design, synthesis, and biological characterization. J Med Chem (2010) 1.01
Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. J Neurosci Res (2007) 1.00
NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamine. Birth Defects Res B Dev Reprod Toxicol (2005) 1.00
Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol Pharm (2010) 1.00
2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-α release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med (2011) 1.00
Mapping the functional yeast ABC transporter interactome. Nat Chem Biol (2013) 0.98
"Inactive" excipients such as Cremophor can affect in vivo drug disposition. Clin Pharmacol Ther (2003) 0.97
Expression of rat hepatic multidrug resistance-associated proteins and organic anion transporters in pregnancy. Am J Physiol Gastrointest Liver Physiol (2002) 0.96
Ca(2+)-dependent protein kinase C isoforms are critical to estradiol 17beta-D-glucuronide-induced cholestasis in the rat. Hepatology (2008) 0.96
The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy. J Pharm Sci (2009) 0.95
Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats. Am J Physiol Gastrointest Liver Physiol (2003) 0.95
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet (2013) 0.95
Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos (2010) 0.94
Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther (2006) 0.94
Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev (2002) 0.94
Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther (2005) 0.94
A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol (2007) 0.94
Alpha 1A-adrenergic receptor polymorphism and vascular response. Clin Pharmacol Ther (2004) 0.93
Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice. Mol Cancer Ther (2006) 0.93
Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics (2010) 0.93
Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17β-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology (2010) 0.92
Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol (2002) 0.92
Role of microtubules in estradiol-17beta-D-glucuronide-induced alteration of canalicular Mrp2 localization and activity. Am J Physiol Gastrointest Liver Physiol (2004) 0.92
The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport. J Biol Chem (2003) 0.92
Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol (2009) 0.91
Mrp1 localization and function in cardiac mitochondria after doxorubicin. Mol Pharmacol (2009) 0.91
5-Oxo-ETE analogs and the proliferation of cancer cells. Biochim Biophys Acta (2005) 0.91
Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin. Drug Metab Dispos (2009) 0.90
Estradiol represses prolactin-induced expression of Na+/taurocholate cotransporting polypeptide in liver cells through estrogen receptor-alpha and signal transducers and activators of transcription 5a. Endocrinology (2003) 0.90
Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One (2011) 0.90
Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet (2012) 0.89
Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. Drug Metab Dispos (2011) 0.89
Formation and efflux of ATP-binding cassette transporter substrate 2,4-dinitrophenyl-S-glutathione from cultured human term placental villous tissue fragments. Mol Pharm (2009) 0.89